🏛️ Verified NIH Record • Updated 2026-08-26

Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans (NCT07216781)

Evaluating the Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans: An Interventional, Non-Placebo-Controlled Pilot Phase Study

🔵 Active, Not Recruiting Phase1 📋 Clinical Research Protocol Sponsor: Minicircle

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to investigate the safety and efficacy of a gene therapy for Klotho, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of the Klotho gene therapy.

Who can join: Review the eligibility criteria below.

Location: Apeiron Center — Austin, Texas

Age range: 23 Years to 90 Years

🧪 Interventions in This Study

  • Injectable Plasmid Klotho Gene Therapy (GENETIC)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (2 Sites)

  • Apeiron Center — Austin, Texas
  • GARM Clinic — Roatán, Bay Islands

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Healthy Adults clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗